Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Molecular Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17164775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies

  2006cited by this paper
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

  2006cited by this paper
• Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.

  2006cited by this paper
• Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A.

  2006cited by this paper
• Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer.

  2005cited by this paper
• Therapy Insight: cardiovascular complications associated with muscular dystrophies

  2005cited by this paper
• Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

  2005cited by this paper
• Muscles of mice deficient in alpha-sarcoglycan maintain large masses and near control force values throughout the life span.

  2005cited by this paper
• Molecular and cell biology of the sarcoglycan complex

  2005cited by this paper
• Femoral intra‐arterial injection: a tool to deliver and assess recombinant AAV constructs in rodents whole hind limb

  2005cited by this paper
• Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

  2003cited by this paper
• Force impairment in calpain 3–deficient mice is not correlated with mechanical disruption

  2003cited by this paper
• Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity.

  2002cited by this paper
• MUSEAP, a novel reporter gene for the study of long-term gene expression in immunocompetent mice.

  2001cited by this paper
• Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies

  2001cited by this paper
• Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer.

  2000cited by this paper
• Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice

  2000cited by this paper
• Full Functional Rescue of a Complete Muscle (TA) in Dystrophic Hamsters by Adeno-Associated Virus Vector-Directed Gene Therapy

  2000cited by this paper
• Transduction and Utility of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Monocytes and Dendritic Cells by Adeno-Associated Virus

  2000cited by this paper
• Filamin 2 (Fln2)

  2000cited by this paper
• Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences

  1999cited by this paper
• Expression of the Primary Coxsackie and Adenovirus Receptor Is Downregulated during Skeletal Muscle Maturation and Limits the Efficacy of Adenovirus-Mediated Gene Delivery to Muscle Cells

  1999cited by this paper
• Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector

  1999cited by this paper
• Sarcoglycan Isoforms in Skeletal Muscle*

  1999cited by this paper
• rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy

  1999cited by this paper
• Bidirectional Signaling between Sarcoglycans and the Integrin Adhesion System in Cultured L6 Myocytes*

  1998cited by this paper
• Progressive Muscular Dystrophy in α-Sarcoglycan–deficient Mice

  1998cited by this paper
• Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer

  1998cited by this paper
• Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using delta-sarcoglycan gene transfer.

  1998cited by this paper
• Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy.

  1997cited by this paper
• Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors

  1997cited by this paper
• Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy.

  1994cited by this paper
• Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin).

  1993cited by this paper
• Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle

  1990cited by this paper
• A noninvasive procedure to detect muscle weakness in the mdx mouse

  1990cited by this paper
• FURTHER OBSERVATIONS ON THE PATHOLOGICAL RESPONSES OF RAT SKELETAL MUSCLE TO TOXINS ISOLATED FROM THE VENOM OF THE AUSTRALIAN TIGER SNAKE, NOTECHIS SCUTATUS SCUTATUS

  1978cited by this paper

• Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives

  2025cites this paper
• Mesenchymal Stem Cells: A New Generation of Therapeutic Agent Vehicles in Gene Therapy.

  2020cites this paper
• [Sarcoglycanopathies: state of the art and therapeutic perspectives].

  2020cites this paper
• Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back

  2020cites this paper
• The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan-Deficient Muscular Dystrophy.

  2019cites this paper
• Plasmid-Mediated Gene Therapy in Mouse Models of Limb Girdle Muscular Dystrophy

  2019cites this paper
• AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice

  2018cites this paper
• Molecular Therapies for Muscular Dystrophies

  2018cites this paper
• Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy

  2017cites this paper
• 1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15-16 November 2016, Evry, France.

  2017cites this paper
• Emerging therapeutic strategies for sarcoglycanopathy

  2017cites this paper
• Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies

  2016cites this paper
• Systemic delivery of adeno-associated viral vectors.

  2016cites this paper
• Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.

  2016cites this paper
• Lineage Plasticity and Regenerative Potential of Adult Muscle Stem Cells: Investigation of Satellite Cell Direct-Reprogramming and Pericyte Self-Renewal

  2016cites this paper
• Vascular Regeneration in Ischemic Hindlimb by Adeno‐Associated Virus Expressing Conditionally Silenced Vascular Endothelial Growth Factor

  2016cites this paper
• Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies?

  2016cites this paper
• Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors

  2015cites this paper
• Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer.

  2015cites this paper
• Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies

  2015cites this paper
• 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands.

  2015cites this paper
• The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.

  2015cites this paper
• Advances in gene therapies for limb-girdle muscular dystrophies

  2014cites this paper
• A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer

  2014cites this paper
• Evaluating Properties of Dystrophin and Delivery Methods of rAAV Gene Therapy for Duchenne Muscular Dystrophy

  2014cites this paper
• Animal models for metabolic, neuromuscular and ophthalmological rare diseases

  2013cites this paper
• Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy

  2013cites this paper
• Prolonged Gene Expression in Muscle Is Achieved Without Active Immune Tolerance Using MicrorRNA 142.3p-Regulated rAAV Gene Transfer

  2013influential citation
• Voluntary physical activity protects from susceptibility to skeletal muscle contraction-induced injury but worsens heart function in mdx mice.

  2013cites this paper
• Integration Frequency and Intermolecular Recombination of rAAV Vectors in Non-human Primate Skeletal Muscle and Liver.

  2012cites this paper
• Cell–matrix interactions in muscle disease

  2012cites this paper
• Long-Term Preservation of Cardiac Structure and Function After Adeno-Associated Virus Serotype 9-Mediated Microdystrophin Gene Transfer in mdx Mice

  2012cites this paper
• Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

  2012cites this paper
• Myofiber Damage Evaluation by Evans Blue Dye Injection

  2011cites this paper
• Methods for noninvasive monitoring of muscle fiber survival with an AAV vector encoding the mSEAP reporter gene.

  2011cites this paper
• AAV-directed muscular dystrophy gene therapy

  2010cites this paper
• Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer.

  2010cites this paper
• Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy.

  2010cites this paper
• Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

  2010cites this paper
• Nouveaux outils exploratoires et développement d'approches thérapeutiques dans les dysferlinopathies primaires

  2010cites this paper
• Interventions for muscular dystrophy: molecular medicines entering the clinic.

  2009cites this paper
• Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects

  2009cites this paper
• Prevention of cardiomyopathy in d -sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors

  2009cites this paper
• Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors.

  2009cites this paper
• Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins

  2009cites this paper
• Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D

  2008cites this paper
• Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle

  2008cites this paper
• Limb-girdle muscular dystrophies.

  2008cites this paper
• Heterogeneous pathogenesis of LGMD 2 : consequences for therapy

  2008cites this paper
• AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis

  2008cites this paper
• Recombinant Adeno-Associated Virus Type 8-Mediated Extensive Therapeutic Gene Delivery into Skeletal Muscle of α-Sarcoglycan-Deficient Mice

  2008influential citation
• Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation.

  2008cites this paper
• Sarcoglycans take center stage in gene transfer therapy

  2008cites this paper
• A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice.

  2008cites this paper
• Genetic Vaccines and Therapy

  2008cites this paper
• Therapeutic approaches for the sarcomeric protein diseases.

  2008cites this paper
• Too much hype, not enough hope: are balanced reporting and proper controls too much to expect from therapeutic studies in animal models of neuromuscular diseases that presage clinical trials in humans?

  2007cites this paper
• A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy

  2007cites this paper
• Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D.

  2007cites this paper
• AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not α-sarcoglycan deficiency

  2007cites this paper
• Ins and outs of therapy in limb girdle muscular dystrophies.

  2007cites this paper